Targeted Oncology46m
FDA Fast Tracks Amezalpat for HCC Treatment
Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma.
Science Daily3h
Candidate genes in canine hepatocellular carcinoma for molecular targeted therapy
Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...
Cancer doctor shares which five types of the disease are most 'lethal'
A cancer expert has shared the five types of cancer which are considered the most "lethal", and claimed people diagnosed with ...
Cancer Therapy Advisor12h
Amezalpat Gets Fast Track Designation for HCC
The FDA has granted fast track designation to amezalpat for the treatment of patients with hepatocellular carcinoma.
Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma
Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCCAmezalpat builds momentum with both ...
Frontiers4d
Using Oncolytic Viruses in Cancer Immunity and Immunotherapy: Hepatocellular Carcinoma, Gastric Cancer, and Colorectal Cancer
Oncolytic viruses (OVs) are viruses that infect and kill cancer cells while sparing healthy tissue, making them a promising therapeutic option in cancer ...
The American Journal of Managed Care12d
Atezolizumab Fails to Help in High-Risk Triple-Negative Breast Cancer
Atezolizumab (Tecentriq) plus chemotherapy after surgery did not improve survival in high-risk triple-negative breast cancer, ...
Targeted Oncology5d
FDA Grants Key Oncology Approvals and Designations in January 2025
On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...